CTOs on the Move

HiberCell

www.hibercell.com

 
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.hibercell.com
  • 619 West 54th Street 8th Floor
    New York, NY USA 10019
  • Phone: 212.601.2800

Executives

Name Title Contact Details

Funding

HiberCell raised $60.7M on 02/07/2019
HiberCell raised $67.4M on 05/19/2021
HiberCell raised $30M on 05/19/2021

Similar Companies

Croda

Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Federation Bio

Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.

Rejuvenate Bio

Rejuvenate Bio is developing novel therapies to treat aging and age-related diseases through innovative targeted gene therapies, is developing treatments to reverse aging and address multiple age-related diseases.

Aerin Medical

Aerin`s advanced treatment platform utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion. Treatment styluses are uniquely designed for each procedure and deliver energy to the target tissue surface without the need for incisions or tissue penetration.Proprietary algorithms ensure that targeted tissues are exposed to carefully controlled energy resulting in treatment temperatures that are below the tissue ablation range. The technology is protected by a comprehensive patent estate consisting of both method and design patents.

Reaction Biology

Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 1,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result.